Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

NCT06104228 is registered in ClinicalTrials.gov with Bastiaan Driehuys as lead sponsor.

NCT NCT06104228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06104228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
Lead sponsor
Bastiaan Driehuys
Phase
Phase 2
Overall status
Recruiting
Start date
August 12, 2024
Completion date
March 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

connective tissue diseases, idiopathic pulmonary arterial hypertension, pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease (disorder)